PATENT CLAIM ANALYSIS

Application Number: 16063170
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Claim (Index 26):
A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a combination comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is a TrkC inhibitor; the second agent is a MEK inhibitor or an ERK inhibitor; and the patient has at least one genetic alteration in NTRK3.

Metadata:
- Claim Count in Document: 131.0
- Percentile: 94.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11581865', '15350801', '15683630', '13893141', '13461098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.74548692584558
- 35 USC 102 Novelty (BERT): 0.5319971719787661
- Combined Prediction Score: 0.7241379504588986
- Mean Citation Score: 309.54825199999993
- Max Citation Score: 333.0288
- Similarity Product: 242.09347640590667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test